These studies have demonstrated that miR-133a-3p may play a critical role in the occurrence and development of ovarian cancer through the Wnt/β-catenin signaling pathway, and that PYGB could be a key diagnostic marker and therapeutic target for the treatment of ovarian cancer. This evidence concerns the gene PYGB and ovarian cancer.